Timing of Low-Dose Aspirin Discontinuation Before C-Section with Spinal Anesthesia
Guideline-Based Recommendations
- The National Comprehensive Cancer Network guidelines recommend stopping low-dose aspirin 1-2 weeks prior to delivery when neuraxial anesthesia is planned, allowing for adequate platelet function recovery while minimizing thrombotic risk during the discontinuation period 1, 2
- Aspirin can be discontinued 1-2 weeks before expected labor or planned delivery, according to the National Comprehensive Cancer Network guidelines 1, 2
- When Low Molecular Weight Heparin (LMWH) is also being used, consultation with an obstetric anesthesiologist is recommended regarding optimal timing for epidural/spinal anesthesia, as per the National Comprehensive Cancer Network guidelines 1, 2
Neuraxial Anesthesia Safety Considerations
- For spinal anesthesia in pregnant patients on low-dose aspirin with normal platelet counts, the procedure can be categorized as "increased risk" but is generally safe when aspirin is discontinued appropriately, with a platelet count >75 × 10⁹/L and normal coagulation confirmed 3
- When combined with LMWH, the LMWH must be stopped for >12 hours in addition to aspirin discontinuation, to minimize bleeding risk 3
- Platelet count should be checked within 6 hours of the procedure in patients with pre-eclampsia or other risk factors, to ensure adequate platelet function 3
Practical Algorithm for Your Patient
- For a planned C-section with spinal anesthesia, aspirin should be discontinued 7-10 days before the scheduled procedure, providing an adequate safety margin based on platelet recovery data 1, 2
- Platelet count and coagulation studies should be checked if there are any signs of pre-eclampsia, platelet count concerns during pregnancy, or if the patient has been on LMWH for >4 days 3
- Ensure platelet count >75 × 10⁹/L immediately before spinal anesthesia, to minimize bleeding risk 3
- Do not restart aspirin until 24 hours after surgery when bleeding risk is deemed acceptable, as recommended by the National Comprehensive Cancer Network guidelines 1, 2, 4